Doxorubicin+Ifosfamide+Anlotinib(AI+A)
ApprovedSmall molecule
Doxorubicin+Ifosfamide+Anlotinib(AI+A) is one of 6 small molecule programs targeting Retroperitoneal Sarcoma. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Retroperitoneal Sarcoma
#DrugCompanyPhaseTrials
1Preoperative Chemotherapy
EEuropean Organisation for Research and Treatment of Cancer - EORTC
Phase 3
RAD001
NovartisPhase 2
Doxorubicin+Ifosfamide+Anlotinib(AI+A)
PPeking University International Hospital
Approved
Verzenio
Eli LillyPhase 1
Liposomal Bupivacaine
TTLC Biopharmaceuticals, Inc.
Phase 2
Adriamycin
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details